- Conditions
- Glioblastoma, Malignant Glioma, Brain Tumors, Anaplastic Astrocytoma
- Interventions
- Stem Cell Radiotherapy (ScRT) and Temozolomide
- Radiation
- Lead sponsor
- Beth Israel Medical Center
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Lung Cancer
- Interventions
- adjuvant therapy, diagnostic thoracoscopy, therapeutic thoracoscopy, video-assisted surgery, radiation therapy
- Procedure · Radiation
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1994 – 2005
- U.S. locations
- 13
- States / cities
- Denver, Colorado • Des Moines, Iowa • Boston, Massachusetts + 8 more
- Conditions
- Ewing Sarcoma, Osteosarcoma, Neuroblastoma, Acute Lymphoblastic Leukemia, Neurofibromatosis Type 1
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 35 Years
- Enrollment
- 1,720 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2020
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Advanced Non-Small Cell Lung Cancer, Squamous Cell Carcinoma, Advanced NSCLC, Adenosquamous Carcinoma, Adenocarcinoma
- Interventions
- Aldesleukin, Fludarabine, Cyclophosphamide, Young TIL
- Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 72 Years
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2027
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Clear Cell Renal Cell Carcinoma, Locally Advanced Clear Cell Renal Cell Carcinoma, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
- Interventions
- Adavosertib
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 29
- States / cities
- Orange, California • Sacramento, California • San Francisco, California + 18 more
- Conditions
- Metastatic Oral Cavity Carcinoma, Recurrent Oral Cavity Carcinoma, Stage IVC Lip and Oral Cavity Cancer AJCC v8, Head and Neck Cancer, Hypopharynx Cancer, Oropharynx Cancer, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Hypopharyngeal Carcinoma, Metastatic Laryngeal Carcinoma, Metastatic Malignant Head and Neck Neoplasm, Metastatic Oropharyngeal Carcinoma, Recurrent Hypopharyngeal Carcinoma, Recurrent Laryngeal Carcinoma, Recurrent Malignant Head and Neck Neoplasm, Recurrent Oropharyngeal Carcinoma, Stage IVC Hypopharyngeal Carcinoma AJCC v8, Stage IVC Laryngeal Cancer AJCC v8, Stage IVC Oropharyngeal (p16-Negative) Carcinoma AJCC v8
- Interventions
- Celecoxib, Erlotinib Hydrochloride, Imaging Procedure, Interview, Methotrexate, Questionnaire Administration
- Drug · Procedure · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Carcinoma, Renal Cell
- Interventions
- SU011248
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 15
- States / cities
- Duarte, California • Pasadena, California • San Francisco, California + 9 more
- Conditions
- Basal Cell Carcinoma, Keratosis Palmaris et Plantaris, Psoriasis
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1977 – 2001
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Glioblastoma
- Interventions
- Pembrolizumab, Bevacizumab, Re-irradiation
- Drug · Radiation
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 5
- States / cities
- Boston, Massachusetts • New York, New York • Philadelphia, Pennsylvania
- Conditions
- Stage II Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7
- Interventions
- Durvalumab, Tremelimumab
- Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Oropharyngeal Squamous Cell Carcinoma, HPV-mediated Oropharyngeal Squamous Cell Carcinoma
- Interventions
- Radiation Therapy
- Radiation
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Hepatocellular Carcinoma (HCC)
- Interventions
- Melphalan/HDS, Sorafenib
- Device · Drug
- Lead sponsor
- Delcath Systems Inc.
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 2
- States / cities
- Tampa, Florida • New York, New York
- Conditions
- Healthy Volunteers, Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC), Esophageal Squamous Cell Carcinoma, Cervical Cancer, Endometrial Cancer, Ovarian Cancer
- Interventions
- RAD301 ([68Ga]-RAD301)
- Drug
- Lead sponsor
- Radiopharm Theranostics, Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2026
- U.S. locations
- 2
- States / cities
- Princeton, New Jersey • The Bronx, New York
- Conditions
- Unresectable Pancreatic Cancer, Cholangiocarcinoma Non-resectable
- Interventions
- Radiofrequency Ablation using EndoHPB Probe, Stenting only
- Procedure
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Pancreas Cancer, Metastatic Pancreatic Cancer, Pancreatic Adenocarcinoma, Metastatic Adenocarcinoma
- Interventions
- Modified GCN+TTF treatment
- Combination Product
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Non-Muscle Invasive Bladder Cancer (NMIBC)
- Interventions
- Bacillus Calmette-Guérin (BCG), Gemcitabine
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 8
- States / cities
- Hartford, Connecticut • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more
- Conditions
- Renal Cell Cancer, Prostate Cancer, Effects of Chemotherapy
- Interventions
- CORA- Device:smartphones"
- Other
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Salivary Gland Cancer, Advanced Salivary Gland Carcinoma, Metastatic Salivary Gland Cancer, Adenoid Cystic Carcinoma
- Interventions
- Ivonescimab
- Drug
- Lead sponsor
- Glenn J. Hanna
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- temozolomide, 3'-deoxy-3'-[18F]fluorothymidine, pharmacological study, Mibefradil
- Drug · Other
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • Atlanta, Georgia • Baltimore, Maryland + 4 more
- Conditions
- Adult Glioblastoma
- Interventions
- specialized tumor board recommendation
- Other
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mixed Epithelial Carcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Undifferentiated Adenocarcinoma, Stage III Ovarian Epithelial Cancer, Stage IV Ovarian Epithelial Cancer
- Interventions
- paclitaxel, cisplatin, topotecan hydrochloride, filgrastim
- Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1996
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Head and Neck Cancer
- Interventions
- Fludarabine Phosphate, Radiation Therapy (RT)
- Drug · Radiation
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1995 – 2002
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Breast Cancer, Pancreatic Cancer, Colorectal Cancer, Carcinoma, Non-Small-Cell Lung, Adenocarcinoma
- Interventions
- MORAb-066
- Drug
- Lead sponsor
- Morphotek
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 2
- States / cities
- Oklahoma City, Oklahoma • Nashville, Tennessee
- Conditions
- Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
- Interventions
- erlotinib hydrochloride, pharmacological study, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 1
- States / cities
- Houston, Texas